[Edaravone in amyotrophic lateral sclerosis]
Groppo J, Augustovski F, Alfie V, Perelli L, Cantos J, García Marti S, Bardach A, Pichon Riviere A, Alcaraz A, Ciapponi A
Record ID 32018012831
Spanish
Original Title:
Actualización - edaravona en esclerosis lateral amiotrófica
Authors' recommendations:
"Conclusions
No comparative evidence on adding edaravone to standard of care (with our without riluzole) has been found. Therefore, relevant outcomes such as mortality or quality of life are uncertain.
Moderate quality evidence shows that adding edaravone to the standard of care with riluzole in patients with amyotrophic lateral sclerosis probably produces a marginal net benefit, as it decreases the disease progression rating scale score during the first year. However, the differences observed were not clinically significant and were not reflected in the follow-up at a longer term. In addition, no differences in the probability of patient survival were observed.
None of the five clinical practice guidelines found mention or recommends the use of this technology, except for the Canadian guideline that recommends adding edaravone to standard of care with riluzole.
As regards the health policies surveyed, edaravone is not covered by national agencies from Europe and Latin America countries; however, it is financed by private agencies in the Unites States of America and Canada.
In Argentina, the use of edaravone is not included in the Mandatory Medical Program and it cannot be recovered through the Unique Reimbursement System for Disease Management.
The cost-effectiveness and budget impact evaluations surveyed suggest that edaravone is not a cost-effective treatment and has a high budget impact."
Details
Project Status:
Completed
URL for project:
https://ets.iecs.org.ar/publication/2097
Year Published:
2023
URL for published report:
https://ets.iecs.org.ar/publication/2097
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Amyotrophic Lateral Sclerosis
- Riluzole
- Edaravone
- Neuroprotective Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.